GlaxoSmithKline (GSK) and XenoPort (XNPT) In Agreement for XP13512
More News related to GSK
- InvestorSoup.com Stock Alerts on: Evergreen Solar, GlaxoSmithKline, Intrepid Potash, Discovery Labs and Nissan
- Piper Jaffray Downgrades Phase Forward (PFWD) to Neutral; Lack of Near-Term Catalysts
- Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Society of Hispanic Professional Engineers Elects New National Board With Raytheon's Manny Hernandez as President
More News related to XNPT
- Piper Jaffray Maintains an Overweight on XenoPort (XNPT); Price Target Increased
- XenoPort (XNPT) Reports Preliminary Results from Phase 2 Trial of XP19986
- XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
- XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference
- Ladenburg Thalmann Upgrades Xenoport (XNPT) to Buy
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced an exclusive agreement to co-develop and commercialize XP13512, a unique prodrug of gabapentin that improves its bioavailability, in the US and other countries worldwide, excluding certain Asian countries.
XP13512 is currently in Phase III development for Restless Legs Syndrome and in Phase II development for neuropathic pain. Prior clinical trial results have been encouraging.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
